You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
寶萊特(300246.SZ)擬斥1億元設立全資子公司加快公司在血液淨化業務領域做強做大
格隆匯 08-16 19:15

格隆匯8月16日丨寶萊特(300246.SZ)公佈,公司於2019年8月16日召開第六屆董事會第三十一次會議,審議通過了《關於投資設立廣東寶萊特血液淨化科技有限公司(暫定)的議案》。

擬設立廣東寶萊特血液淨化科技有限公司(暫定名,以工商登記機關最終核准名稱為準)經營範圍:體外循環及血液淨化系列產品的研發、技術諮詢及自有技術轉讓服務;醫療器械、儀器設備及其零配件以及與產品相關的軟件產品的研發、製造、銷售及技術諮詢與服務;生物材料、醫用高分子材料、特種複合材料及製品、精細化工材料的研發、製造、銷售及技術諮詢與服務;醫用計算機軟件產品的開發、銷售及系統管理與維護(法律、法規和國務院決定禁止的不得經營;依法須經批准的項目,經相關部門批准後方可開展經營活動);醫療科技、專用設備、信息科技、生物科技領域內的技術開發、技術轉讓、技術推廣服務、技術諮詢;兼營自有房屋租賃、機械設備租賃;自營和代理各類商品和技術的進出口業務(國家限定企業經營或禁止進出口的商品和技術除外)。(最終以工商登記機關核准的經營範圍為準)。註冊資本1億元。公司出資1億元,佔註冊資本的100%。

公司致力於打造血液淨化領域的全產業鏈佈局,要在日漸競爭激烈中勝出,需加大投資力度、投入更多資源和精力做大做強血液淨化業務板塊,逐步打響寶萊特在血液淨化領域的品牌。

此次投資設立全資子公司廣東寶萊特血液淨化科技有限公司是寶萊特集團公司重視血液淨化業務的重要舉措,為了更大程度統領、融合公司在血液淨化領域的產業鏈優勢、渠道網絡優勢、基地佈局優勢、規模優勢和協同作用,集中資源和力量來加快公司在血液淨化業務領域做強做大,籍此推動並加快健康監測板塊的轉型升級,最終將對公司的業績增長髮揮積極作用。

公司持續多年在血液淨化領域深耕細作,通過自主研發與外延併購,從透析設備(機)、灌流機、透析用制水設備、消毒系統、濃縮液集中配供液系統、透析耗材(透析器,透析液過濾器,透析粉/液,消毒液,透析管路,穿刺針等)、銷售渠道與平台、醫療醫院服務等全面佈局血液淨化生態圈。其中渠道方面,在國內擁有三家渠道平台公司,公司產品目前已經覆蓋國內近5000家醫院、覆蓋海外100多個國家和地區。

目前,公司在國內形成了廣東、江蘇、江西、湖北、遼寧、重慶、天津七大產業基地,初步完成全國性戰略佈局;實施“走出去,帶回來”國際化戰略,公司德國血液淨化產業園基地初步建成,德國基地採用德國乃至歐洲在血液淨化領域的先進管理人才、經驗和技術,將推進血液透析設備及關鍵耗材的國產化進程,促進公司國內相關質量、管理和效益的提升。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account